Chemoresistance is associated with MUC1 and lewis y antigen expression in ovarian epithelial cancers

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 11024-11033

  Zhang, Danye ^a   Gao, Jian ^a   Zhu, Liancheng ^a   Hu, Zhenhua ^a   Hou, Rui ^a   Liu, Shuice ^a   Tan, Mingzi ^a   Liu, Juanjuan ^a   Lin, Bei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Immunohistochemistry; Lewis y antigen; MUC1; Ovarian epithelial cancer

Indexed keywords

ANTIGEN; LEWIS Y ANTIGEN; MUCIN 1; PLATINUM COMPLEX; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; BLOOD GROUP LEWIS SYSTEM;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT OUTCOME; BLOOD GROUP LEWIS SYSTEM; DRUG RESISTANCE; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEWIS BLOOD-GROUP SYSTEM; MUCIN-1; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84878438650     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140611024     Document Type: Article

References (27)

1. Budiu, R.A.; Mantia-Smaldone, G.; Elishaev, E.; Chu, T.; Thaller, J.; McCabe, K.; Lenzner, D.; Edwards, R.P.; Vlad, A.M. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol. Immunother. 2011, 60, 975-984.
2. Hazlehurst, L.A.; Dalton, W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001, 20, 43-50.
3. Moro, L.; Venturino, M.; Bozzo, C.; Silengo, L.; Altruda, F.; Beguinot, L.; Tarone, G.; Defilippi, P. Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 1998, 17, 6622-6632.
4. Hasegawa, H.; Komoda, M.; Yamada, Y.; Yonezawa, S.; Tsutsumida, H.; Nagai, K.; Atogami, S.; Tsuruda, K.; Osaka, A.; Sasaki, D.; et al. Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells. Leuk Lymphoma 2011, 52, 1108-1117.
5. Ye, Q.; Yan, Z.; Liao, X.; Li, Y.; Yang, J.; Sun, J.; Kawano, T.; Wang, X.; Cao, Z.; Wang, Z.; Huang, L. MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab. Invest. 2011, 91, 778-787.
6. Yan, L.; Lin, B.; Zhu, L.; Hao, Y.; Qi, Y.; Wang, C.; Gao, S.; Liu, S.; Zhang, S.; Iwamori M. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin α5β1 with the Lewis Y-structure on transfection of the α1,2-fucosyltransferase gene. Biochimie 2010, 7, 852-857.
7. Engelstaedter, V.; Heublein, S.; Schumacher, A.L.; Lenhard, M.; Engelstaedter, H.; Andergassen, U.; Guenthner-Biller, M.; Kuhn, C.; Rack, B.; Kupka, M.; et al. Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients. BMC Cancer 2012, 12, 600.
8. Van Elssen, C.H.; Frings, P.W.; Bot, F.J.; van de Vijver, K.K.; Huls, M.B.; Meek, B.; Hupperets, P.; Germeraad, W.T.; Bos, G.M. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 2010, 57, 597-606.
9. Feng, H.; Ghazizadeh, M.; Konishi, H.; Araki, T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn. J. Clin. Oncol. 2002, 32, 525-529.
10. Cheng, J.P.; Yan, Y.; Wang, X.Y.; Lu, Y.L.; Yuan, Y.H.; Jia, J.; Ren, J. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer. Chin. J. Cancer 2011, 30, 54-61.
11. Al-azawi, D.; Kelly, G.; Myers, E.; McDermott, E.W.; Hill, A.D.; Duffy, M.J.; Higgins, N.O. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006, 6, 220.
12. Uchida, Y.; Raina, D.; Kharbanda, S.; Kufe, D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biol. Ther. 2013, 14, 127-134.
13. Raina, D.; Kharbanda, S.; Kufe, D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J. Biol. Chem. 2004, 279, 20607-20612.
14. Yin, L.; Li, Y.; Ren, J.; Kuwahara, H.; Kufe, D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J. Biol. Chem. 2003, 278, 35458-35464.
15. Raina, D.; Ahmad, R.; Kumar, S.; Ren, J.; Yoshida, K.; Kharbanda, S.; Kufe, D. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006, 25, 3774-3783.
16. Ren, J.; Agata, N.; Chen, D.; Li, Y.; Yu, W.H.; Huang, L.; Raina, D.; Chen, W.; Kharbanda, S.; Kufe, D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004, 5, 163-175.
17. Simpson, C.; Anyiwe, K.; Schimmer, A. Anoikis resistance and tumor metastasis. Cancer Lett. 2008, 2, 177-185.
18. Siragusa, M.; Zerilli, M.; Iovino, F.; Francipane, M.G.; Lombardo, Y.; Ricci-Vitiani, L.; di Gesu, G.; Todaro, M.; de Maria, R.; Stassi, G. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res. 2007, 67, 5522-5530.
19. Ahmad, R.; Alam, M.; Rajabi, H.; Kufe, D. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J. Biol. Chem. 2012, 287, 20866-20875.
20. Wei, X.; Xu, H.; Kufe, D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005, 7, 167-178.
21. Wernyj, R.P.; Morin, P.J. Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel. Drug Resist. Updat. 2004, 7, 227-232.
22. Agarwal, R.; Kaye, S.B. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502-516.
23. Horm, T.M.; Schroeder, J.A. MUC1 and metastatic cancer: Expression, function and therapeutic targeting. Cell Adh. Migr. 2013, 7, 187-198.
24. Yuan, Z.; Wong, S.; Borrelli, A.; Chung, M.A. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem. Biophys. Res. Commun. 2007, 362, 740-746.
25. Chien, J.R.; Aletti, G.; Bell, D.A.; Keeney, G.L.; Shridhar, V.; Hartmann, L.C. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J. Cell Biochem. 2007, 102, 1117-1129.
26. Gao, L.; Yan, L.; Lin, B.; Gao, J.; Liang, X.; Wang, Y.; Liu, J.; Zhang, S.; Iwamori, M. Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I. J. Exp. Clin. Cancer Res. 2011, 30, 15.
27. Gao, S.; Liu, Q.; Wang, X.; Lin, B.; Zhang, S. Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med. Oncol. 2010, 27, 960-967.